Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.BMX, and TEC, respectively) and no activity against EGFR.
Acalisib (GS-9820) is a potent and selective PI3Kδ inhibitor with an IC50 of 12.7 nM, with potential immunomodulating and antineoplastic activities.
Acalisib (GS-9820) is a potent and selective PI3Kδ inhibitor with an IC50 of 12.7 nM, with potential immunomodulating and antineoplastic activities.
Acalisib (GS-9820) is a potent and selective PI3Kδ inhibitor with an IC50 of 12.7 nM, with potential immunomodulating and antineoplastic activities.
Acalisib (GS-9820) is a potent and selective PI3Kδ inhibitor with an IC50 of 12.7 nM, with potential immunomodulating and antineoplastic activities.
Acamprosate calcium (Campral EC) is a GABA receptor agonist and glutamate system modulator.
Acamprosate calcium (Campral EC) is a GABA receptor agonist and glutamate system modulator.
Acarbose (BAY G 5421) is an alpha-glucosidase inhibitor with oral activity (IC50=11 nM). Acarbose can enhance the hypoglycemic effect of sulfonylurea inhibitors or insulin.
Acarbose (BAY G 5421) is an alpha-glucosidase inhibitor with oral activity (IC50=11 nM). Acarbose can enhance the hypoglycemic effect of sulfonylurea inhibitors or insulin.
Acarbose (BAY G 5421) is an alpha-glucosidase inhibitor with oral activity (IC50=11 nM). Acarbose can enhance the hypoglycemic effect of sulfonylurea inhibitors or insulin.
ACBI1 is an effective and synergistic PROTAC inhibitor of SMARCA2, SMARCA4 and PBRM1, with DC50 of 6 nM, 11 nM and 32 nM in MV-4-11 cells, respectively. ACBI1 can induce antiproliferative effect and apoptosis.
ACBI1 is an effective and synergistic PROTAC inhibitor of SMARCA2, SMARCA4 and PBRM1, with DC50 of 6 nM, 11 nM and 32 nM in MV-4-11 cells, respectively. ACBI1 can induce antiproliferative effect and apoptosis.